2019, Number 2
<< Back Next >>
Med Int Mex 2019; 35 (2)
Successful use of omalizumab in patients with overlap syndrome asthma-COPD in a University Hospital of Puebla
Herrera-García JC, Arellano-Montellano EI, Jaramillo-Arellano LE, Espinoza- Arellano A
Language: Spanish
References: 10
Page: 298-301
PDF size: 170.59 Kb.
ABSTRACT
The term asthma/COPD, called SOAE (overlap asthma/EPOC acronym in English ACOS
[asthma COPD overlap syndrome]), includes a subset of patients with persistence and
airflow limitation that presents clinical features of both asthma and COPD. Lack of
consensus on a definition of ACOS has led to the wide range in prevalence ranging between
11 and 56% in COPD, 13 and 61% in asthma, and 2% in the general population.
The initial studies have shown that omalizumab may be useful in patients with ACOS,
it has been shown to improve symptoms, reduce exacerbations and hospitalization,
as well as improve lung function parameters and reduce steroid requirement in these
patients. This paper describes the effect of omalizumab in 5 patients with a diagnosis
of overlying asthma/COPD syndrome (SOAE) and administration of omalizumab. We
describe the experience of our center and the benefits that the treatment has given to
our patients. These benefits have allowed the patient a better quality of life and radically
reduce their morbidity.
REFERENCES
Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med 2015;373:1241-1249.
Sin DD, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016. DOI: 10.1183/13993003.00436- 2016.
Cosio, et al. Definiting the asthma-COPD overlap syndrome in COPD cohort. Chest. 2016;149(1):45-52.
Kiljander T, Helin T, Venho K, Jaakkola A, Lehtimaki L. Prevalence of asthma-COPD overlap syndrome among primary care asthmatics with a smoking history: A cross-sectional study. NPJ Prim Care Respir Med July 2015. DOI: 10.1038/ npjpcrm.2015.47
Rodrigues D, Galego MA, Teixeira M, Vaz AP, Ferreira J. Characterization of ACOS patients in pulmonary outpatient consultation-applying the questionnaire by GINA/GOLD consensus. Eur Respir J 2016. DOI: 10.1183/13993003. congress- 2016.PA869.
Herrera J, et al. Prevalence of asthma-COPD patients in pulmonary department and asthma/COPD clinic consultation: A cohort study: in press.
Yalcin AD, Celik B, Yalcin AN. Omalizumab anti-IgE therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. Immunopharmacol Immunotoxicol Jun 2016;38(3). DOI: 10.3109/08923973.2016.1173057.
Busse WW, et al. Clinical preview, biologicals for asthma in patients with asthma-COPD overlap syndrome. Lancet March 2017;5:176-177.
Nayci SA, Ozgur E, Tastekin E, Ozge C. Effectiveness of omalizumab treatment in Asthma-COPD Overlap syndrome In: Chest Annual Meeting 2016. 22-26 Los Angeles, Cal. DOI: http//dx-doi.org/101016/j.chest.2016.08.967.
Dammert P, Jawahar D. Omalizumab in patients with COPD and atopic phenotype: A case series. Am J Respir Crit Care Med 2016;193:A6246.
Full text